Kestrel Therapeutics's Phase III readout in NF2 landed without a press cycle. The 31% objective response rate, in a population with vanishingly few options, deserved more attention than it got.
Meridia Pharma's commercial team will be doing the math on a rare-disease price point that pays back the platform investment without requiring a blockbuster.
